Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Rises By 3,333.9%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 374,300 shares, a growth of 3,333.9% from the September 30th total of 10,900 shares. Based on an average daily volume of 715,100 shares, the short-interest ratio is currently 0.5 days.

Chugai Pharmaceutical Stock Performance

CHGCY stock traded up $0.34 during midday trading on Friday, reaching $22.83. 54,915 shares of the company were exchanged, compared to its average volume of 129,767. The company has a market cap of $75.11 billion, a price-to-earnings ratio of 33.57 and a beta of 0.89. The stock’s 50-day simple moving average is $23.90 and its 200 day simple moving average is $19.71. Chugai Pharmaceutical has a 1-year low of $14.10 and a 1-year high of $26.00.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. The business had revenue of $2.03 billion during the quarter. On average, research analysts anticipate that Chugai Pharmaceutical will post 0.78 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.